Striatal Medium Spiny Neurons In Huntington'S Disease is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
Medium Spiny Neurons (MSNs) are the primary output neurons of the striatum, constituting 90-95% of striatal neurons. In Huntington's disease (HD), MSNs are selectively vulnerable, leading to the characteristic motor, cognitive, and psychiatric symptoms.
| Feature | Change | Clinical Impact |
|---|---|---|
| Count | ↓↓ 60-80% | Bradykinesia |
| D1 receptor | ↓ | Movement initiation |
| Axonal projections | Degenerated | Motor deficits |
| Feature | Change | Clinical Impact |
|---|---|---|
| Count | ↓ 40-60% | Dyskinesias |
| D2 receptor | ↓ | Movement suppression |
| Axonal projections | Degenerated | Motor control |
| Neurotransmitter | Change | Effect |
|---|---|---|
| Dopamine | ↓↓ | Movement disorders |
| GABA | ↓↓ | Network dysfunction |
| Acetylcholine | ↓ | Cognitive deficits |
| Glutamate | ↑ (excitotoxicity) | Neuronal death |
The study of Striatal Medium Spiny Neurons In Huntington'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Vonsattel, J.P., et al. (1985). Neuropathology of Huntington's Disease. Journal of Neuropathology & Experimental Neurology.
[2] Reiner, A., et al. (1988). Differential Vulnerability of MSN Subtypes. Brain Research.
[3] Graybiel, A.M. (2000). The Basal Ganglia and Chunking. Current Opinion in Neurobiology.
[4] Cepeda, C., et al. (2007). HD Striatal Vulnerability. Brain Research Reviews.
[5] Ross, C.A., et al. (2014). Huntington Disease: Pathogenesis and Treatment. Lancet Neurology.